- ►diabetesjournals.org J Plank, A Wutte, G Brunner, A Siebenhofer, … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—With respect to blood glucose excursions from time 0 to 6 h (Exc
glu(0–6 h) ) and from time 0 to 4 h (Exc glu(0–4 h) ), the pharmacodynamic
effect of insulin aspart and insulin lispro can be declared equivalent. ... Cited by 76 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org B Bode, R Weinstein, D Bell, J McGill, D … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Treatment groups had similar baseline HbA 1c (7.3% ±0.7 for IAsp,
7.5% ±0.8 for BR, and 7.3% ±0.7 for lispro). After 16 weeks of treatment, HbA
1c values were relatively unchanged from baseline, and the mean changes in ... Cited by 122 - Related articles - BL Direct - All 20 versions
- ►diabetesjournals.org C Homko, A Deluzio, C Jimenez, JW … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Seven C-peptide–negative patients with type 1
diabetes (two men and five women) were studied at the General Clinical Research
Center at Temple University Hospital two times, 1 month apart. Their plasma ... Cited by 65 - Related articles - BL Direct - All 6 versions
MA Von Mach, C Brinkmann, T Hansen, LS … - Experimental and Clinical Endocrinology & Diabetes, 2002 - thieme-connect.com Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin
analogues lispro and aspart were compared in a randomized, double-blind
crossover study of 20 fasting healthy men following a single subcutaneous ... Cited by 31 - Related articles - BL Direct - All 4 versions
- Free from Publisher T Danne, J Aman, E Schober, D Deiss, JL … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glycemic control for postprandial treatment was not worse than
preprandial treatment as assessed by fructosamine week 0 vs. 6 (mean ± SD,
preprandial 367 ± 74 vs. 378 ± 90 μmol/l; postprandial 383 ± 83 vs. 385 ... Cited by 61 - Related articles - BL Direct - All 7 versions
- ►epgasia.com [PDF] - Free from Publisher BW Bode, P Strange - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE— The purpose of this study was to compare the efficacy, safety, and
pump compatibility of insulin aspart (a rapid-acting insulin analog) and
buffered regular human insulin in patients with type 1 diabetes undergoing ... Cited by 83 - Related articles - BL Direct - All 13 versions
P Raskin, JH Holcombe, WV Tamborlane, JI … - Journal of diabetes and its complications, 2001 - Elsevier This study compared glycemic control achieved with insulin lispro or buffered
regular human insulin in patients with Type 1 diabetes treated with continuous
subcutaneous insulin infusion (CSII) using an external insulin pump. In ... Cited by 65 - Related articles - BL Direct - All 11 versions
- ►diabetesjournals.org [PDF] CA Hedman, T Lindström, HJ Arnqvist - Diabetes Care, 2001 - Am Diabetes Assoc Two rapid-acting insulin analogs, lis- pro and aspart, are now available for
clinical use (1). The aim of our study was to compare the plasma-insulin
profiles of these ana- logs after subcutaneous injection in pa- tients with ... Cited by 57 - Related articles - BL Direct - All 6 versions
A Siebenhofer, J Plank, A Berghold, K Jeitler, … - Cochrane Database Syst Rev, 2006 - medscape.com A Cochrane Review Abstract: Evidence Based Medicine reviews based primarily
on meta-analysis of controlled clinical trials.
Cited by 112 - Related articles - All 7 versions
JH DeVries, A Lindholm, JL Jacobsen, RJ … - Diabetic Medicine, 2003 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 20 - Related articles - BL Direct - All 4 versions
